Nexalin Technology SVP Departs; Company Discloses Separation Terms

What Happened Nexalin Technology, Inc. (NXL) filed a Form 8-K (Item 5.02) on September 2, 2026, reporting that Carolyn Shelton left her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs effective August 28, 2026. The company and Ms. Shelton entered a separation agreement that specifies continued pay, a bonus, accelerated option vesting, extended exercise periods, and short-term health insurance subsidy. The full separation agreement will be filed as an exhibit to Nexalin’s next periodic report.

Key Details

• Effective departure date: August 28, 2026. 8-K filed: September 2, 2026.
• Cash and pay: one month of continued base salary and a 2026 bonus of $20,000.
• Equity: accelerated vesting of unvested stock options and up to two years to exercise vested options.
• Benefits and other terms: company will subsidize health insurance premiums through September 30, 2026; Ms. Shelton provided a release of claims and agreed to confidentiality, non‑disparagement, and cooperation obligations.

Why It Matters This filing informs investors of a senior executive departure and the company’s cost and contractual commitments tied to that departure. The specified cash payment, bonus, accelerated option vesting and extended exercise window could have modest near-term compensation and equity‑related impacts. The company’s disclosure of a formal separation agreement provides transparency about severance and governance-related provisions that affect executive transitions.